151751-Najiba-Chargi

323 Systemic therapy: skeletal muscle mass and functional outcomes Table 1. Baseline characteristics of patients at t0, t1 and t2. P values shown for Kruskal-Wallis Testa, linear-by-linear approximation of the Pearson’s Chi-square Testb, Mann Whitney U testc or Fisher’s exact testd. t 0 n = 108 t 1 n = 99 t 2 n = 71 P value t 0, t 1, t 2 Only t 0 available n = 34 P value t 0, only t 0 Not included because no t0 available n = 84 P value t 0, no t 0 Gender Male 73 (68) 68 (69) 52 (73) .461 b 24 (71) .834 d 54 (64) .648 d Female 35 (32) 31 (31) 19 (27) 10 (29) 30 (36) Age at baseline Median (range) 63 (39–81) 63 (39–81) 60 (39–77) .499 a 65 (49–78) .316 c 62 (47-83) .530 c ACE-27 0 53 (49) 46 (47) 39 (55) .357 b 14 (41) .248 b 37 (44) .442 b 1 37 (34) 35 (35) 26 (37) 10 (29) 30 (36) 2 14 (13) 14 (14) 3 (4) 9 (27) 13 (16) 3 4 (4) 4 (4) 3 (4) 1 (3) 4 (5) BMI Median (range) 25 (17-44) 25 (17-44) 26 (17-44) .791 a 24 (49-78) .127 d SMM Median (range) 44 (22-64) 44 (22-64) 45 (22-64) .506 a Sarcopenia No 59 (55) 53 (54) 44 (62) .402 b Yes 49 (45) 46 (47) 27 (38) Oropharyngeal tumor site Base of tongue 35 (32) 33 (33) 25 (35) .819 b 13 (38) .888 b 31 (37) .685 b Tonsil 57 (53) 54 (55) 35 (49) 13 (38) 33 (39) Other 16 (15) 12 (12) 11 (16) 8 (24) 20 (24) T classification T1 27 (25) 23 (23) 19 (27) .832 b 4 (12) .006 b 22 (26) .791 b T2 30 (28) 30 (30) 19 (27) 8 (24) 28 (33) T3 29 (27) 25 (25) 20 (28) 5 (15) 14 (17) T4 22 (20) 21 (21) 13 (18) 17 (50) 20 (24) N classification N0 12 (11) 11 (11) 8 (11) .794 b 3 (9) .589 b 6 (7) .205 b N1 24 (22) 22 (22) 13 (18) 7 (21) 14 (17) N2 69 (64) 63 (64) 48 (68) 22 (65) 62 (74) N3 3 (3) 3 (3) 2 (3) 2 (6) 2 (2) AJCC stage III 28 (26) 25 (25) 18 (25) .931 b 4 (12) .102 d 17 (20) .394 d IV 80 (74) 74 (75) 53 (75) 30 (88) 67 (80) HPV status Negative 33 (32) 31 (31) 18 (26) .454 b 14 (47) .192 d 29 (40) .267 d Positive 70 (68) 64 (67) 51 (74) 16 (53) 43 (60) 17